Materials and Methods

Patients
The study group comprised 20 patients who underwent potentially curative resection for primary PDA at Kyoto University Hospital from 2006 to 2011 (Table 1) . Written informed consent for the use of their resected tissues was obtained from all patients in accordance with the Declaration of Helsinki, and the Kyoto University Graduate School and Faculty of Medicine Ethics Committee approved the study.
Mice
The generation of AID Tg mice with constitutive and ubiquitous AID expression was described previously (24) . Wild-type (WT) C57BL/6J mice were purchased from Japan SLC, INC. (Shizuoka, Japan). For immunohistochemistry, tissue samples were removed from the mice, flushed with 1×PBS, fixed overnight in 4% (w/v) formaldehyde, and embedded in paraffin. Tissue samples were also frozen immediately in liquid nitrogen for nucleotide extraction. 
Histology and Immunohistochemistry
Paraffin-embedded human and mouse pancreatic tissues were sectioned and stained with hematoxylin and eosin. Paraffin-embedded mouse pancreatic tissues were also stained with Alcian blue and nuclear fast red. Immunohistochemistry was performed according to the manufacturer's recommendations, typically using a citric acid unmasking protocol followed by standard detection with 3,3-diaminobenzidine using a LSAB+ kit (DAKO, Glostrup, Denmark) or VECTASTAIN ABC Kit (Vector Laboratories, Burlingame, CA). All sections were counterstained with hematoxylin. A polyclonal antibody against human AID was generated using purified recombinant AID protein as an immunogen (28). In addition, we used the following primary antibodies: cytokeratin 19 Genome DNA was extracted from frozen pancreatic tissues of mice using a DNA Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. We analyzed 1 AID Tg mouse and 1 WT mouse at 13 months of age. The mutational status of Kras, c-Myc, and Trp53 DNA was investigated by deep sequencing analyses. Target regions were designed within the range from 388 to 409 bp. The primer sequences are described in Supplementary Table S1 . Each region was amplified with high-fidelity PCR using Phusion High-Fidelity DNA polymerase (FINNZYMES, Espoo, Finland), purified by gel-extraction methods. A 500-ng aliquot of each sample was dA-tailed and ligated with adaptors containing tag sequences, followed by emulsion PCR and sequencing using the GS Junior System (Roche, Madison, WI) according to the manufacturer's protocol.
Deep sequencing data were analyzed with NextGENe software, v2.3.4 (SoftGenetics, State College, PA). We identified low-abundance somatic mutations using a strict variant filtering process. We excluded nucleotide changes that were common between WT and AID Tg mice. Candidate low-abundance mutations were validated by repeated deep sequencing using independent amplicons derived from the same samples. According to our previous result (29), we picked the mutations that presented at a frequency greater than 0.1%. order using a laser capture microdissection technique from PALM Technologies (Carl Zeiss Microimaging, Jena, Germany) or Leica AS LMD (Leica, Wetzlar, Germany).
Dissected tissues were catapulted into caps by defocused laser pulses. Representative photographs before and after microdissection of PanIN are shown in Supplementary Figure S1 . Next, the xylene was removed from the dissected samples and the DNA was extracted using the QIAamp DNA Micro Kit (Qiagen) according to the manufacturer's protocol.
Subcloning and sequencing of the tumor-related genes
Genomic DNA from the laser capture microdissection samples was prepared using the DNA Micro Kit (Qiagen) according to the manufacturer's protocol. The primers used for amplifying Kras, c-Myc, and Smad4 are described in Supplementary Table S2 . After amplifying each gene using high-fidelity Phusion Taq polymerase (FINNZYMES), the PCR products were subcloned by insertion into the EcoRI-XhoI sites of the pcDNA3 vector (Invitrogen, Carlsbad, CA) and further subjected to capillary sequence analyses.
Results
Expression of AID protein in human PDA and precancerous lesions
To clarify the specific expression and precise localization of AID protein in human pancreatic tissues, immunohistochemistry was performed using various paraffin-embedded specimens from patients with PDA. We found ADM in 9/20 (45%), PanIN-1A/1B in 9/20 (45%), and PanIN-2/3 in 6/20 (33%) PDA specimens. We examined the AID immunoreactivity in each lesion. AID immunoreactivity was detected Table 2 ). AID protein expression tended to increase with progression from precancerous lesions to invasive cancer. Notably, we occasionally detected AID protein expression in acinar cells adjacent to human PDA tissues. In normal pancreatic ducts, we observed no AID protein expression (Fig. 1B) . We confirmed that no immunostaining was obtained when non-immunized serum or PBS was used instead of the antibodies against AID (Fig. 1B) . AID protein expression was also detected in ADM and PanIN lesions in human chronic pancreatitis as well as PDA tissues (Fig. 1C) .
Immunohistochemistry of serial sections confirmed that these AID protein expressions were accompanied by p65 nuclear translocation suggesting NF-κB activation (Fig. 1C) .
Development of ADM and PanIN in AID Tg mouse pancreas
Previous studies reported that AID Tg mice with systemic and ubiquitous AID expression develop four types of tumors, including lymphoma, hepatocellular carcinoma, gastric cancer, and lung cancer (30). In the present study, we focused on the pancreatic phenotypes, and examined the pancreatic pathology in detail in AID Tg mice at 3, 6, 11, and 13 months of age. AID Tg mice developed tubular structures with both acinar and ductal differentiation, which is consistent with human ADM. ADM showed co-expression of acinar (amylase) and ductal (CK19) markers, consistent with a previous report ( Fig.   2A ) (31). AID Tg mice also developed ductal lesions with histologic and molecular characteristics of human PanIN, including a high acidic mucin content indicated by Alcian blue staining and CK19 expression ( Fig. 2A) . These ductal lesions were low-grade PanINs that weakly expressed amylase and CK19, consistent with a previous study (32). Another previous report revealed that MAPK signaling activation is required for the initiation and maintenance of pancreatic precancerous lesions in the PDA mouse model (33) . Therefore, we next examined phospho-Erk1/2 (p-Erk1/2) expression in pancreatic precancerous lesions that developed in AID Tg mice, and confirmed the activation of MAPK signaling in both ADM and PanIN in AID Tg mice ( Fig. 2A ).
We found ADM in 2/5 (40%), 4/4 (100%), and 7/7 (100%) AID Tg mice at 6, 11, and 13 months of age, respectively. We also found PanIN lesions in 1/4 (25%) and 4/7 (57%) AID Tg mice at 11 and 13 months of age, respectively, whereas no PanIN was detected at 3 and 6 months of age (Table 3 ). At 13 months of age, remarkable atrophic changes in pancreas, decreased acinar cells, and ductal lesions were observed in some AID Tg mice (e.g., AID Tg 13M-2). Thus, the frequencies of ADM and PanIN increased with age, and ADM development appeared to precede the development of PanIN ( Fig. 2B and 2C ).
On the other hand, the WT mice did not develop ADM or PanIN, even at 13 months of age (Fig. 2C, Table 3 ).
Mutational profiles of AID Tg mice pancreas analyzed by deep sequencing
To investigate the mutational profiles of tumor-related genes in the AID Tg mouse whole pancreas, we extracted DNA from the pancreas of 1 AID Tg and 1 WT mouse at 13 months of age, and subjected them to deep sequencing on the selected amplicons of the tumor-related genes. We selected three representative tumor-related genes, including Kras and Trp53 that are frequently mutated in human PDA, and c-Myc, which was recently reported to play a significant role in the progression and maintenance of PDA (34) . An overall mean coverage depth of 10975 was achieved for each nucleotide site. An overall mean coverage depth of 4950, 15300, and 12595 was achieved for each nucleotide site in Kras, Trp53, and c-Myc, respectively. Deep sequencing of the selected genes identified that Kras and c-Myc were mutated in AID Tg, but not in WT mouse pancreas. We found three and four point mutations in Kras and c-Myc, respectively (Table 4A ). The positions of the Kras mutations were codon 10 (c.30A>G, p.G10G), codon 20 (c.60G>A, pT20T), and c.37+20C>T. On the other hand, deep sequencing revealed that Trp53 was not mutated in AID Tg or WT mouse pancreas (Table 4A) .
Recent reports led us to speculate on the molecular process underlying the mutation induction by analyzing the pattern of nucleotide alterations (35) (36) (37) (38) . Among the cytidine deaminase family proteins, AID shows a strong preference for deaminating C residues flanked by a 5'-purine (G or A) (38) (39) (40) . In contrast, APOBEC3 family enzymes and APOBEC1 favor C residues flanked by 5'-T (41, 42) . Therefore, we investigated the pattern of nucleotide alterations in the AID Tg mouse pancreas. Of a total of seven point mutations, three mutations (43%) were C:G>T:A transitions. In addition, all three C:G>T:A transitions were in the context of GpCpX, showing the typical mutational footprint of AID (Table 4B) .
To further elucidate the global mutational profile of AID Tg mouse pancreas, we 
and WT mouse, respectively (Supplementary Table S3 ). According to the variant filtering process ( Supplementary Fig. S2A ), we identified 124 somatic mutations in 57 genes with 33% of C:G>T:A transitions in AID Tg pancreatic tissue, indicating broad spectrum of genotoxic effect of AID on entire genome (Supplementary Fig. S2B ). Table 5 . Of the 9 point mutations detected in Kras, c-Myc, and Smad4, two (22%) were C:G>T:A transitions in the context of GpCpX or ApCpX, a typical mutation pattern induced by AID (Table 5 ). These results indicate that the deamination induced by AID is involved in the mutational signature of pancreatic tumorigenesis in mice.
Mutations of tumor-related genes in precancerous lesions
Discussion
Although it is well-established that an accumulation of genetic abnormalities plays a crucial role in the development of PDA, the mechanisms underlying the induction of tumor-related gene mutations has remained unexplained. A role for the AID/APOBEC family members in carcinogenesis was recently proposed (35) (36) (37) . Given that more than half of the mutations in PDA are C:G>T:A substitutions (27), a typical AID/APOBEC mutation pattern, we explored the possible contribution of AID to the mutagenesis underlying the development of PDA. In the present study, we found substantial AID expression, not only in human PDA, but also in precancerous lesions. Furthermore, we Further, we confirmed that the AID protein was expressed in human pancreatic precancerous lesions (ADM and PanIN) as well as in invasive cancer, whereas no AID expression was detected in normal pancreatic ducts. This AID expression in human pancreatic cancer was also supported by RNAseq data sets derived from The Cancer Genome Atlas (TCGA) (43) . These findings suggest that AID is involved in the initiation of pancreatic cancer development. Our immunohistochemistry also suggests that these AID expressions in human precancerous and PDA lesions could be induced by some inflammatory stimulus through NF-κB activation as previously shown in other organs Although we observed the development of ADM and PanIN, we detected no PDA development in the AID Tg mice. This could be due to an insufficient observation period.
Almost all AID Tg mice develop lethal lymphoma and die at 12 to 13 months of age (24), and thus we could not observe the phenotypes of AID Tg mice beyond 13 months of age.
Further studies to analyze the generation of pancreas-specific AID transgenic mice are required.
The KRAS gene mutation is thought to play an essential role in the initiation of PDA. Further experiments are required, however, to determine whether these mutations found in AID Tg mouse pancreas are pathogenic.
Recent studies demonstrated that the mutation signature that accumulates in tumor tissues provides a key to identifying the cause of mutations during tumorigenesis (25,37). In this regard, the mutation signature of AID is characterized by C:G>T:A alterations that occur in the GpCpX or ApCpX sequences (38) (39) (40) (50) (51) (52) Immunohistochemistry of serial sections confirmed that these AID protein expressions were accompanied by p65 nuclear translocation suggesting NF-κB activation (arrowheads in lower panels, scale bars: 100µm). 
